Literature DB >> 28561726

Caring for the Older Population With Advanced Lung Cancer.

Carolyn J Presley1, Craig H Reynolds1, Corey J Langer1.   

Abstract

The management of advanced lung cancer is changing rapidly, with new drug approvals occurring almost monthly. The average age of a newly diagnosed patient with advanced lung cancer remains around age 70. Caring for the older adult with advanced cancer differs from the care of younger adults. Chronologic age often does not accurately reflect the physiologic and functional status of older adults. Selecting treatment based on age alone results in undertreatment and overtreatment of many older adults. Addressing issues such as multiple chronic conditions, polypharmacy, geriatric syndromes, and heterogeneity in functional status among an expanding menu of treatment options for advanced disease is increasingly difficult, particularly among older adults historically underrepresented in clinical trials. In this article, we highlight key issues in caring for the older adult with advanced non-small cell lung cancer and the continued need for data supporting current and emerging treatment options. Key issues include the unique challenges of managing advanced lung cancer and a summary of the current treatment evidence as they apply to the elderly lung cancer population including supportive care strategies, risk stratification, and patient-reported outcomes.

Entities:  

Mesh:

Year:  2017        PMID: 28561726     DOI: 10.1200/EDBK_179850

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  5 in total

Review 1.  Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations.

Authors:  Isabela M Bumanlag; Joseph Abi Jaoude; Michael K Rooney; Cullen M Taniguchi; Ethan B Ludmir
Journal:  Semin Radiat Oncol       Date:  2022-04       Impact factor: 5.934

2.  Geographic and socioeconomic considerations for glioblastoma treatment in the elderly at a national level: a US perspective.

Authors:  Victor M Lu; Cole T Lewis; Yoshua Esquenazi
Journal:  Neurooncol Pract       Date:  2020-06-03

3.  Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer.

Authors:  Yusuke Yonenaga; Tateaki Naito; Taro Okayama; Midori Kitagawa; Noriko Mitsuhashi; Takeshi Ishii; Hiroshi Fuseya; Toshimi Inano; Ayumu Morikawa; Miwa Sugiyama; Keita Mori; Akifumi Notsu; Takanori Kawabata; Akira Ono; Hirotsugu Kenmotsu; Haruyasu Murakami; Akira Tanuma; Toshiaki Takahashi
Journal:  J Multidiscip Healthc       Date:  2021-06-21

4.  Active Treatment Improves Overall Survival in Extremely Older Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study.

Authors:  Su Yeon Lee; Yoon-Ki Hong; Wonjun Ji; Jae Cheol Lee; Chang Min Choi
Journal:  Cancer Res Treat       Date:  2020-10-05       Impact factor: 4.679

5.  The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study.

Authors:  Yuichiro Ohe; Naoya Yamazaki; Nobuyuki Yamamoto; Haruyasu Murakami; Kiyotaka Yoh; Shigehisa Kitano; Hideyuki Hashimoto; Ayako Murayama; Sayuri Nakane; Akihiko Gemma
Journal:  Jpn J Clin Oncol       Date:  2022-05-31       Impact factor: 2.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.